Grifols reported EUR9.95B in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
aTyr Pharma USD 1.72M 10.79M Mar/2026
Bio Path USD 0 0 Mar/2025
Brainstorm Cell Therapeutics USD 0 0 Mar/2025
Capricor Therapeutics USD 3.38M 0 Mar/2025
Cara Therapeutics USD 0 0 Mar/2025
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Grifols EUR 9.95B 722.93M Dec/2025
Immunic USD 0 0 Jun/2024
Minerva Neurosciences USD 0 86.58M Sep/2024
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
TherapeuticsMD USD 0 0 Mar/2022